Digital Marketing Associate

Waltham, MA (Remote)

$70K/yr – $100K/yrMid Level3+ years expFull time

That's a $30K range, and it's not just about skills.

Where you land depends on how well you negotiate. Practice with our AI agent. That's the best ROI of any 15 minutes you'll spend this year.

Start practicing

Posted 2 days ago

Job Summary

Original Job Description

Spend 15 mins, increase your paycheck by $15,000

$15,000 more per year. $45,000 over a 3-year tenure. One practice session with AI. That's the best ROI of any 15 minutes you'll spend this year.

Get Started

Naveris logo

Naveris

Glassdoor
3.8

Naveris® Inc. is a molecular diagnostics company developing and commercializing novel blood and saliva tests to enhance the early detection and clinical management of viral-associated cancers. The company’s NavDx® blood test, which uses proprietary technology to detect tumor tissue modified viral (TTMV®)-HPV DNA, is in use at leading cancer treatment centers and academic medical centers throughout the United States.www.naveris.comwww.navdx.com

Marketing team
5
Employees
115
Headquarters
Waltham, Massachusetts, USA
Founded
2017

Employee Sentiment

Overall Rating
3.8 / 5
Recommend to a Friend
53%
Source: Glassdoor

Traffic Signals

Monthly Visitors
2.4K
Monthly Google Ads Budget
$0.0
Traffic Source Mix
Search
27.3%
Direct
48.3%
Referral
6%
Social
16.9%
Paid
1.4%

Headcount Trend

Current headcount: ~117

Marketing Team

Marketing Team Size
5 (4% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$66.3M
Last Raise
2 years ago
Last Raise Amount
$17.5M
  • 2024-07-02T00:00:00.000Z
    Series Unknown • $17.5M
  • 2022-09-19T00:00:00.000Z
    Series A • $33.4M
  • 2020-12-15T00:00:00.000Z
    Series A

Recent News

Yahoo Finance
Naveris Introduces Advanced NavDx+Gyn™ Test for Early Detection of HPV-Driven Gynecologic Cancers
Mar 27, 2025
Business Wire
Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance
Jan 10, 2025
BioSpace
Naveris Announces Expansion of the NavDx® Test in Anal Cancer Molecular Residual Disease Surveillance
Jan 10, 2025